doi:10.3969/j.issn.1673-8640.2015.06.026

Abstract

CLC Number:

R446.1

Figures/Tables 1

References 8

[1]	戴晓燕,刘彦风,阳智勇.不稳定型心绞痛、心肌梗死患者甲状腺激素水平的测定及其临床意义[J].中西医结合心脑血管病杂志,2012, 10(11):1301-1303.
[2]	中华医学会心血管病学分会,中华心血管病杂志编辑委员会,《中国循环杂志》编辑委员会.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志,2001,29(12):710-725.
[3]	托马斯. 临床实验诊断学-实验结果的应用和评估[M].上海:上海科学技术出版社,2004:1013.
[4]	王征,张福春,崔鸣.甲状腺素在急性心肌梗死中变化特点及短期预后价值[J].中华老年多器官疾病杂志,2013,12(4):254-257.
[5]	PAVLOU HN,KLIRIDIS PA,PANAGIOTOPOULOS AA,et al.Euthyroid sick syndrome in acute ischemic syndromes[J].Angiology,2002,53(6):699-707.
[6]	莫恩健,李炎梅,梁太英,等.急性心肌梗死患者治疗前后甲状腺激素水平变化分析[J].中国临床新医学,2012,5(12):1120-1122.
[7]	IERVASI G,PINGITORE A,LANDI P,et al.Low-T3 syndrome:a strong prognostic predictor of death in patients with heart disease[J].Circulation,2003,107(5):708-713.
[8]	郭静,张雪艳,郑丽珺.急性心肌梗死患者血清FT3、FT4的变化及其临床意义[J].临床军医杂志,2010,38(5):761.

组别	例数	TT3(ng/mL)	FT3(pg/mL)	TT4(μg/L)	FT4(ng/L)	TSH(μIU/mL)
AMI组	50	0.66±0.12^*	2.04±0.33^*	67.60±14.00	10.30±1.80	1.04±0.85
NSTEMI组	16	0.73±0.21	2.11±0.25	71.70±12.00	10.50±1.10	1.07±0.90
STEMI组	34	0.70±0.12	2.14±0.35	68.50±16.00	9.50±1.80	0.98±0.82
正常对照组	50	0.92±0.12	2.60±0.22	65.60±12.00	10.00±1.00	1.58±0.79

组别	例数	TT3(ng/mL)	FT3(pg/mL)	TT4(μg/L)	FT4(ng/L)	TSH(μIU/mL)
AMI组	50	0.66±0.12^*	2.04±0.33^*	67.60±14.00	10.30±1.80	1.04±0.85
NSTEMI组	16	0.73±0.21	2.11±0.25	71.70±12.00	10.50±1.10	1.07±0.90
STEMI组	34	0.70±0.12	2.14±0.35	68.50±16.00	9.50±1.80	0.98±0.82
正常对照组	50	0.92±0.12	2.60±0.22	65.60±12.00	10.00±1.00	1.58±0.79

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 8

Related Articles 15

Recommended Articles

Metrics